Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saye Khoo

Showing results (241-250 of 282) with videos related to

Pageof 29
Sort By:
AIDS Research and Human Retroviruses|June 1, 2019
A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIVRoss D Cranston, Charlene S Dezzutti, Aaron Siegel, et al.
The Lancet. Microbe|April 26, 2026
Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC)David M Lowe, Shengyuan Zhang, Samuel Ellis, et al.
Cytokine|May 2, 2016
CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSFSam Nightingale, Benedict D Michael, Martin Fisher, et al.
AIDS (London, England)|September 29, 2022
Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trialsFrancois Venter, Simiso Sokhela, Alexandra Calmy, et al.
The Journal of Antimicrobial Chemotherapy|February 26, 2013
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoringAlan Winston, Sophie Jose, Sara Gibbons, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 8, 2020
Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase InhibitorsElisabeth Deutschmann, Heiner C Bucher, Steffen Jaeckel, et al.
The Lancet. HIV|May 11, 2020
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trialKenneth Kintu, Thokozile R Malaba, Jesca Nakibuka, et al.
Frontiers in Immunology|August 15, 2022
Mobilization of systemic CCL4 following HIV pre-exposure prophylaxis in young men in AfricaStefan Petkov, Carolina Herrera, Laura Else, et al.
Journal of the International AIDS Society|July 13, 2019
Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defectsLynne M Mofenson, Anton L Pozniak, Jacque Wambui, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 28, 2020
Inflammatory Phenotypes Predict Changes in Arterial Stiffness Following Antiretroviral Therapy InitiationChristine Kelly, Willard Tinago, Dagmar Alber, et al.
Pageof 29

Showing results (241-250 of 282) with videos related to

Sort By:
Pageof 29
AIDS Research and Human Retroviruses|June 1, 2019
A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIVRoss D Cranston, Charlene S Dezzutti, Aaron Siegel, et al.
The Lancet. Microbe|April 26, 2026
Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC)David M Lowe, Shengyuan Zhang, Samuel Ellis, et al.
Cytokine|May 2, 2016
CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSFSam Nightingale, Benedict D Michael, Martin Fisher, et al.
AIDS (London, England)|September 29, 2022
Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trialsFrancois Venter, Simiso Sokhela, Alexandra Calmy, et al.
The Journal of Antimicrobial Chemotherapy|February 26, 2013
Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoringAlan Winston, Sophie Jose, Sara Gibbons, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 8, 2020
Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase InhibitorsElisabeth Deutschmann, Heiner C Bucher, Steffen Jaeckel, et al.
The Lancet. HIV|May 11, 2020
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trialKenneth Kintu, Thokozile R Malaba, Jesca Nakibuka, et al.
Frontiers in Immunology|August 15, 2022
Mobilization of systemic CCL4 following HIV pre-exposure prophylaxis in young men in AfricaStefan Petkov, Carolina Herrera, Laura Else, et al.
Journal of the International AIDS Society|July 13, 2019
Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defectsLynne M Mofenson, Anton L Pozniak, Jacque Wambui, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 28, 2020
Inflammatory Phenotypes Predict Changes in Arterial Stiffness Following Antiretroviral Therapy InitiationChristine Kelly, Willard Tinago, Dagmar Alber, et al.
Pageof 29